2325 GMT - Cochlear shakes off its bear at UBS thanks to the 14% share-price dive that followed the hearing-implant maker's 1H result. Analyst Laura Sutcliffe raises her recommendation on the Australia-listed stock to neutral from sell, telling clients in a note that the result wasn't as bad as it looked. She isn't totally convinced by the company's expectation of 10% implant unit growth in the June half, calling it a big ask. However, she sees Cochlear's confidence in such a growth rate going forward as important. UBS lifts its target price 5.6% to A$285.00. Shares are up 2.6% at A$269.64. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 16, 2025 18:25 ET (23:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.